Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

stuttering as measured by the SSI-3 scale when compared to placebo (p=.02). While receiving 8 weeks of placebo, patients had experienced a mean reduction of approximately 5% in the percentage of syllables stuttered, however after three months of open label treatment, patients achieved a reduction of 31%. These open label gains lagged slightly the gains made by patients originally randomized to 8 weeks of active pagoclone (5 months total exposure), who had, during the double blind phase, experienced a mean reduction of 18% of syllables stuttered and then went on to achieve a reduction of 40% of syllables stuttered after three months of the open label extension.

The SEV, measured at week 2, week 4 and week 8, is a validated measure of stuttering. The SEV is a 9-point, clinician rated severity scale anchored by "no stuttering" and "extremely severe stuttering." The on-treatment effect of patients receiving pagoclone demonstrated a numerically superior rating versus patients treated with placebo (p=.18).

The SSS Severity Subscore, measured at week 2, week 4 and week 8, is a validated, patient-rated assessment of stuttering that takes into account specific speaking situations that have taken place over the prior week. Pagoclone produced a statistically significant reduction at week 2 (p=.004) and week 4 (p=.05) and a trend for significant improvement at week 8 (p=.08) as compared to placebo.

The secondary endpoints evaluated in the study included the Clinician Global Impression-Improvement (CGI-I), the Liebowitz Social Anxiety Scale (LSAS) and the Speech Naturalness Scale (SNS).

The CGI-I, measured at week 2, week 4 and week 8, is a 7-point, validated and widely accepted clinician-rated measure of improvement as compared to baseline, considering all sources of available clinical information about the patient. For analysis of the improvement in the severity of stuttering, patients were categorized as having either "improved" versus "no change
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/16/2014)... who received hypofractionated (HPFX) radiation therapy (RT) reported ... bladder and bowel function were at similar levels ... today at the American Society for Radiation Oncology,s ... parallel quality of life outcomes occurred between groups ... RT. , The phase I/II trial enrolled 343 ...
(Date:9/16/2014)... (parous women) appear to have an increased risk ... that carries a higher mortality rate and is ... A similar relationship was found for triple-negative breast ... risk of estrogen receptor-negative and triple-negative breast cancer ... never breastfed. These findings, published in the ...
(Date:9/16/2014)... of getting prostate cancer after a worldwide team of ... genetic biomarkers, reported in Nature Genetics today. ... Jyotsna Batra and Distinguished Professor Judith Clements, who led ... hubs around the world, said the teams analysed more ... "It,s the largest analysis of genetic biomarkers ever done. ...
(Date:9/16/2014)... 16, 2014 Definitive Healthcare ... and healthcare providers, is pleased to announce the ... online database, now available for subscription, features detailed ... health system affiliations. , The Canadian database spans ... intelligence on over 750 hospitals. Each hospital ...
(Date:9/16/2014)... 16, 2014 Gary F. Locke, the ... has selected Worldwide Speakers Group for exclusive representation of ... of Commerce and Governor of Washington, Locke is widely ... U.S.-China relations, global expansion, and business growth. , “Gary ... and how to grow an organization’s global presence in ...
Breaking Medicine News(10 mins):Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 2Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 3Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2
... by day. The number of infections a person has been ... death from heart attack. It is long been suspected that ... This has been possible by promoting inflammation within the coronary ... have conflicting evidence. ,According to researchers at University ...
... (Dietary Approaches to Stop Hypertension) says by reducing salt ... effective in decreasing blood pressure as antihypertensive medications.In addition, ... decrease in the prevalence of heart disease and a ... ,The DASH-Sodium study included 342 people. More than half ...
... to a new study the use of serotonin-raising drugs ... a stroke. In common the mecahnism of durgs is ... with many different roles in the body.// Examples include ... antidepressants. ,Researchers at the Health welfare hospital, ...
... of the American Chemical Society indicated that cooking vegetables ... our body can absorb from them.// Tung-Ching Lee, a food ... vegetables and found that 25 of them benefited from cooking ... iron content in the vegetable is the same before and ...
... amount of fruit and vegetables, but they are still only a ... a booster to our human system.On an average the percentage of ... increased from 15 per cent to18 per cent between 1993 and ... ,Among women, the percentage increase was from 20 per cent to ...
... impairment. A new hearing device that is implanted in the ... aid. Doctors say that there's now a better option for ... sound through the eardrum, and may produce feedback - distracting ... the feeling of talking within a barrel. ,The ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: